Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Financial Report 4th quarter for DOF ASA

The Group’s revenue for 4th quarter (management reporting) totals NOK 1 680 million (NOK 1 979 million) and the EBITDA totals NOK 606 million (NOK  805 million, adjusted for hedge accounting). The operating profit (EBIT) is NOK -335 million (NOK 98 million), of which depreciation and impairment totals NOK 942 million (NOK 651 million). Net profit is NOK  238 million (NOK -512 million). In summary, 2020 has been a challenging year due to continued downturn in the markets which has increased the pressure on earnings and utilisation. In addition, the COVID-19 virus has continued to impact

Elkem to study carbon capture opportunities with Aker Carbon Capture and Saipem

Elkem’s long term goal is to achieve carbon-neutral metal production. Currently, Elkem is conducting a feasibility study for the establishment of carbon capture at the Norwegian smelters. In connection with the feasibility study, Elkem has entered into agreements with two alternative technology providers: Aker Carbon Capture and Saipem.Elkem, one of the world's leading suppliers of silicon-based advanced materials, has a broad and comprehensive approach to the work of reducing emissions and contributing to a sustainable future. Recently, the company was rated among the world’s leading on

Cereno Scientific publishes year-end report for 2020 (1 January – 31 December 2020)

The Board and Chief Executive Officer of Cereno Scientific AB here presents the year-end report for the year 2020. Summary of the year-end report, January – December 2020Cereno Scientific Group Full year (1 January – 31 December 2020) · Net Sales were 0 SEK · Loss after financial items was SEK 16 017 060 · Loss per share was SEK 0.22 before dilution and SEK 0.21 after dilution · The equity/assets ratio was 88.9 % Fourth quarter (1 October – 31 December 2020) · Net Sales were 0 SEK · Loss after financial items was SEK 5 109 959 · Loss per share was SEK 0.07

FIRST DAY OF TRADING IN DESENIO'S SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SWITZERLAND, SOUTH KOREA OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Desenio Group AB (publ) (“Desenio” or the “Company”), a fast growing online-based direct-to-consumer company within the global market for affordable wall art, today celebrates the first day of trading

New OxThera/Oxabact US patent granted

Stockholm – 25 February 2021. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact announces that a new US patent has been granted for its product candidate Oxabact, and for a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.The first formulation of Oxabact was patented and granted back in 1999. Since 2012, the company has developed a new, high-concentrated formulation of Oxabact designed

Karl-Petter Thorwaldsson to join SSAB

Karl-Petter Thorwaldsson, former president of the Swedish Trade Union Confederation, LO, is to join SSAB as Senior Advisor to strengthen the company’s government relations and public affairs in Sweden and at the EU level. The recruitment is a step in SSAB’s ambition to lead the green transformation in the steel industry, which requires good, close dialogue between industry and society in general. Karl-Petter Thorwaldsson will report directly to Martin Lindqvist, SSAB’s President and CEO.“As one of the largest industrial companies in the Nordic countries, SSAB has taken on a clear leadership

Eurobattery Minerals AB Year-end Report January–December 2020

Fourth quarter 2020 (same period previous year) · Net sales amounted to SEK 0 thousand (SEK 0 thousand). · Operating income after depreciation/amortisation and financial items totalled SEK –5,336 thousand (SEK –2,939 thousand). · Earnings per share after depreciation/amortisation and financial items amounted to SEK –0.34 (SEK –0.30). · Cash flow from operating activities was SEK –5,786 thousand (SEK –3,493 thousand). Full year 2020 (same period previous year) · Net sales amounted to SEK 0 thousand (SEK 0 thousand). · Operating income after depreciation/

CONTINUOUS NEGATIVE IMPACT FROM THE ONGOING PANDEMIC

NOVEMBER 2020–JANUARY 2021 · Revenue: MSEK 2,282 (9,707) · Income before tax (EBT): MSEK -1,936 (-1,087) · Income before tax and items affecting comparability: MSEK -1,948 (-1,078) · Net income for the period: MSEK -2,050 (-861) · Earnings per common share SEK -0.28 (-2.33) SIGNIFICANT EVENTS DURING THE QUARTER · Rickard Gustafson announced his decision to leave SAS after ten years. He will leave the company by July 1, 2021. · SAS and Apollo have extended their charter partnership in the form of a three-year contract valued at SEK 3.4 billion. · SAS contracted

Asarina Pharma AB (publ) Q4 / Year End 2020 report released

Asarina Pharma CEO Peter Nordkild: “2020 was a turbulent, challenging year for all of us - yet at Asarina Pharma we begin 2021 with continued confidence in the high potential of our flagship compound Sepranolone. We are on schedule to publish our topline results for our Phase IIa Menstrual Migraine study in June 2021, and in the same month initiate our Phase IIa study in Tourette syndrome.”FINANCIAL HIGHLIGHTS · R&D costs reflecting termination of PMDD and CMC activities · Staff costs lower due to headcount reduction · Solid cash position at year-end R&D HIGHLIGHTS

Inhalation Sciences Sweden AB (publ) releases its Year-end report for the period January 1 - December 31, 2020

Summary of the year-end report • ISAB has repositioned its CRO business under a new brand name, "Inhalation Research Services", or IRS, offering precise, predictive early-stage research data. • ISAB has installed the first DissolvIt[®] module at a laboratory at an international company in Switzerland. • ISAB has recruited Chief Commercial Officer to strengthen the commercial organization. • ISAB has recruited a Quality and Regulatory Affairs manager to strengthen the organization's regulatory and quality system and support the planned clinical trial. • The company's Board has

Live mode in New QuizDuel scales up in Germany

MAG expands the rollout of New QuizDuel's new live trivia mode to a considerably larger audience in Germany.Stockholm, Sweden - 25 February 2021 - MAG Interactive announces today that the new live mode in New QuizDuel in Germany will be made available to a greatly expanded audience. In December, technical tests of the new game mode began on a smaller scale in the game's largest market, Germany, and have gradually scaled up since then. The new game mode consists of live quizzes with a host and is designed together with Primetime, which was acquired by MAG in the fall of 2020. The live

Year-end report 19/20: Continued strong organic growth, positive result and strategic investments for the future

Fifth quarter (September – December 2020, 4 months) · Net sales amounted to SEK 239,216 thousand (SEK 50,189 thousand), which corresponds to an increase of 377% (118%) compared to the corresponding period a year earlier, of which 73% (47%) was organic growth. The acquisition of Scienion has since September 1, 2020 contributed with SEK 152,176 thousand in sales. · Operating profit before depreciation (EBITDA) amounted to SEK 40,414 thousand (SEK -15,567 thousand), corresponding to a margin of 16.9% (-31.0%). · Profit for the period amounted to SEK 13,219 thousand (SEK -18,895

Workation - be digital nomad in Thailand

  The global spread of COVID-19, the novel coronavirus, is keeping people at home. Work from home has been our new normal lifestyle. Many companies and the governments encourage people to work from home as much as possible and in an indeterminate amount of time and probably will be with us after the pandemic. But we keep dreaming of changing the working environment to get more energy and to be more productive. Thailand is an ideal place to combine vacation and remote working for your new digital nomad lifestyle.  Thanks to today’s technology that makes things more

Year-end report for the period 1 January – 31 December 2020

Fourth quarter of 2020 Numbers in parentheses refers to outcomes during the corresponding period of the previous year. · Operating loss increased to SEK 6.2 million (4.6). · Net loss for the period increased to SEK 6.8 million (-4.5). · Loss per share of SEK 0.2 (0.1).  Significant events in the quarter Management Reinforcement - The company has appointed Aharon Yehuda as Chief Financial Officer for the Eco Wave Power Group. Mr. Yehuda joins Eco Wave Power with broad experience in corporate and operational finance, most recently as the CFO of Turbochrome, a subsidiary

Electrolux publishes 2020 Annual Report

Electrolux Annual Report for 2020 has been published on the Group’s website as of today.The Annual Report can be downloaded in pdf format here  and will be distributed in mid-March 2021 to shareholders who have requested it. “The coronavirus pandemic in 2020 had a severe impact on all aspects of society, including on our consumers and our business. We have all experienced challenging times but I believe that our execution and consumers’ response validate that we have the right strategy in place. The financial

Implantica publishes Interim Report Q4, January-December 2020

“The extraordinary 3-year results of our pivotal RefluxStop™ clinical trial was the highlight of the fourth quarter, with patient data supporting that RefluxStop™ has the attributes to cause a paradigm shift in acid reflux treatment.”- Peter Forsell, CEO and Founder of ImplanticaSignificant events during the fourth quarter, 2020 · Implantica’s RefluxStop™ trial showed exceptional three-year follow-up results. None of the patients in the study were in need of regular daily use of PPIs (proton-pump inhibitors), which were taken by all before surgery. · Implantica completed a pre-

TC TECH Sweden AB (publ) publishes its Summarized Financial Statements

TC TECH has today published its summarized financial statement report for the period January 1 to December 31, 2020.Net sales amounted to 2 (4 358) TSEK in the fourth quarter of 2020. In the same period, net profit/loss totalled -3 182 (-6 007) TSEK. Cash flow from operating activities was -1 487 (-3 991) TSEK in the period from October 1[st] to December 31[st] 2020.  Net sales amounted to 107 (14 193) TSEK in the full year of 2020, while net profit/loss totalled -20 763 (-27 640) TSEK. Cash flow from operating activities was -14 940 (-22 181) TSEK in the period from January 1[st] to

InDex Pharmaceuticals Holding AB (publ) year-end report 2020

Financing secured for phase III development of cobitolimod“With the equity financing secured until the next pivotal read-out of clinical data, it feels very inspiring to now advance cobitolimod into phase III, which is the final stage of development before application for market approval,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period October – December 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –10.1 (–25.6) million · Result after tax amounted to SEK –10.1 (–25.6) million, corresponding to SEK –0.04 per share (–0.11) before

Karnov Group reports fourth quarter and full-year results 2020

Ending the year on a positive noteFINANCIAL HIGHLIGHTS fourth QUARTER · Net sales flat at SEK 189 m (189), organic growth was 1%. · EBITA amounted to SEK 48 m (39) with EBITA margin of 25.2% (20.6%). · Adjusted EBITA increased by 0.6% to SEK 60 m (59) and adjusted EBITA margin was 31.7% (31.4%). · Net result amounted to SEK 16 m (8). · Earnings per share after dilution amounted to SEK 0.16 (0.08). · Adjusted operating cash flow amounted to SEK 192 m (109). FINANCIAL HIGHLIGHTS FULL-YEAR · Net sales up 2% to SEK 771 m (757), organic growth was 2%. · EBITA

Skanska divests multi-family project in Stockholm, Sweden, for about SEK 720 M

Skanska has divested 220 rental apartments in Stockholm, Sweden, to NREP for about SEK 720M. The multi-family project, which is under construction, includes a garage and commercial premises on the ground floor. The transaction will be recorded by Skanska Sweden in the Residential Development stream in the first quarter 2021. The transfer of the property will take place in connection with completion in December 2023.The block, which will comprise 13,600 square meters of housing and premises, has been developed by Skanska Hyresbostäder and is a part of Barkarbystaden, where Skanska in

Platzer’s Annual Report 2020

Platzer’s Annual Report in Swedish is now published.  The English version will be available on our website on March 25, 2021. The Annual General Meeting of Platzer Fastigheter Holding AB (publ) will take place on Wednesday, March 31 2021. Platzer Fastigheter Holding AB (publ) For further information please contact :P-G Persson, vd, Platzer, tel: +46 (0)734-11 12 22Fredrik Sjudin, cfo, Platzer, tel:  +46 (0)721-27 77 78 This information is information that Platzer Fastigheter Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information

Polygiene (publ.) Year End report 2020

Polygiene ends the year with a new sales record and the acquisition of Addmaster ltdQ4 IN BRIEF · The best quarter ever with a net sales of 26.6 (19.0) and a positive growth by 40 % compared to the same period last year. · The operating profit/loss EBIT amounted to MSEK -2.4 (-2.2). · The non-recurring costs associated with the acquisition of Addmaster affected the result with MSEK -2.6. · The gross margin amounted to 64.9 (68.7) %. · The period has a currency effect, net MSEK -1.4. · Despite the non-recurring costs, the cash flow is improved compared to the same quarter

Updated strategy takes Mekonomen Group to SEK 15 billion in sales 2025

- with adjusted EBIT of SEK 1.5 billionToday, Mekonomen Group presents an updated strategy that will increase the company's sales to SEK 15 billion no later than 2025. The company will also reach SEK 1.5 billion in adjusted EBIT. The goal is based on the company's long-term financial target of 5 percent average annual growth and 10 per cent in adjusted EBIT. During Mekonomen Group's digital Capital Markets Day on February 25, starting at 02.00 p.m CET, the company describes the strategy in more detail and how the goals will be achieved. Since 2010, Mekonomen Group has undergone a

Mekonomen Group launches the new E+ standard for electric car service and transforms workshops

Today, Mekonomen Group launches a new standard for electric car service, E+, which guarantees that the workshops have the right skills and equipment to take care of electric cars. The launch is a response to the fact that today there is no clear standard - despite the fact that electric cars are becoming more common and will increase sharply in number in the future. Already next year, Mekonomen Group will have 1,500 electric car workshops that meet the requirements of E+. Electric cars are expected to account for about ten percent of new car sales globally in 2025 and 30 percent of sales

There are no items matching the current filter
There are no more items matching the current filter
Back to top